Clinical trials: Hematopoietic Stem Cell Transplant (HSCT), open to volunteers
Acute Graft Versus Host Disease
First-Line Jaktinib for Acute Graft-Versus-Host Disease (aGVHD)
This study aims to evaluate the optimal dose (Recommended Phase 2 Dose, RP2D), preliminary safety, and efficacy of gecacitinib (also known as jaktinib) in combination with glucocorticoids as first-line therapy for patients with…
- Trial name
- NCT07285889
- Testing
- Gecacitinib (also known as Jaktinib) combined glucocorticoids
- Where
- China
- Volunteers
- 35 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Hematopoietic Stem Cell Transplantation, Thrombocytopenia
Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT
This study employs a prospective, randomized, double-blind, placebo-controlled design. It aims to compare the efficacy of etamsylate versus placebo in preventing bleeding complications in patients with thrombocytopenia following…
- Trial name
- NCT07442513
- Testing
- etamsylate
- Where
- China
- Volunteers
- 404 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Myeloid Chimerism
Repeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease and Falling Donor Myeloid Chimerism Levels
Background: Sickle cell disease can often be treated with blood stem cell transplants. But for some people the disease returns. This study will give a second transplant to people whose disease has returned but still have some…
- Trial name
- NCT04008368
- Testing
- CliniMACS CD34 Reagent
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
CSF1R-related Leukoencephalopathy, ALSP
A Study to Assess CSF1R-related Leukoencephalopathy After Stem Cell Transplantation
The purpose of this study is to measure the effect of Hematopoietic Stem Cell Transplantation (HSCT) on symptoms of CSF1R-related Leukoencephalopathy.
- Conditions
- CSF1R-related Leukoencephalopathy, ALSP, POLD, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT04503213
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Acute Myeloid Leukemia, Graft Versus Host Disease
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
This phase I trial tests the safety, side effects and effectiveness of emapalumab with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil in preventing graft-versus-host disease (GVHD) in patients with acute…
- Conditions
- Acute Myeloid Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome
- Trial name
- NCT06996119
- Testing
- Biospecimen Collection, Busulfan, Computed Tomography
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Acute Graft-versus-Host Disease
A Study of iMSC for the Prevention of Acute Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
An open-label, randomized, controlled clinical trial to explore the efficacy and safety of iMSC in preventing the development of acute graft-versus-host disease of degree III-IV in patients after allogeneic hematopoietic stem…
- Trial name
- NCT06949267
- Testing
- iMSC, conventional aGVHD prophylaxis
- Volunteers
- 56 people
- Sponsor
- Ruijin Hospital
Viral Infection, Hematopoietic Stem Cell Transplantation (HSCT)
Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts
This is a Phase I dose-escalation study to evaluate the safety of norovirus -specific T-cell (NST) therapy for chronic norovirus infection in participants following hematopoietic stem cell transplantation (HSCT) or who are…
- Conditions
- Viral Infection, Hematopoietic Stem Cell Transplantation (HSCT), Primary Immunodeficiency Disorders (PID)
- Trial name
- ATLANTIC (NCT04691622)
- Testing
- Norovirus -specific T-cell (NST) therapy
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Children's National Research Institute
Transplant-Related Disorder
daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT
This study aims to evaluate the efficacy of prophylactic ruxolitinib in adult patients at intermediate-to-high risk of severe acute GvHD, as predicted by the daGOAT model.
- Trial name
- NCT07588945
- Testing
- Ruxolitinib
- Volunteers
- 438 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leukaemia (Acute Lymphoblastic), Leukaemia (Acute Myeloid)
Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma
A first-in-class adoptive immunotherapy we called ThINKK, for Therapeutic Inducers of Natural Killer (NK) cell Killing, have been designed for use after hematopoietic stem cell transplantation (HSCT), where the proper stimulation…
- Conditions
- Leukaemia (Acute Lymphoblastic), Leukaemia (Acute Myeloid), Neuroblastoma, Neuroblastoma, Metastatic
- Trial name
- ThINKK-01 (NCT07518654)
- Testing
- Therapeutic Inducers of Natural Killer Killing (ThINKK)
- Where
- 2 sites in Canada
- Volunteers
- 12 people
- Sponsor
- Michel Duval
Acute Leukemia, Acute Lymphoblastic Lymphoma
Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)
This is a randomized phase II trial of standard-of-care reduced-intensity conditioning (RIC) with 200 versus 400 cGy of total body irradiation (TBI) in patients with acute leukemia undergoing first allogeneic blood or marrow…
- Trial name
- NCT06803745
- Testing
- 200 cGy or 400 cGy total body irradiation (TBI)
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Diabetes Mellitus
Abnormal Glucose Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation
To investigate the impact of abnormal glucose tolerance in hematopoietic stem cell transplantation donors on patients' post-transplant survival outcomes.
- Conditions
- ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Diabetes Mellitus, Impaired Fasting Glucose
- Trial name
- NCT06704542
- Where
- 6 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Ruijin Hospital
Myelodysplastic Syndromes
Age-Stratified Conditioning Regimen Efficacy for MDS Haplo-HSCT
This study plan aims to enroll adult patients diagnosed with myelodysplastic syndrome (MDS) who are scheduled to receive T-cell-replete haploidentical hematopoietic stem cell transplantation.
- Trial name
- NCT07677306
- Testing
- RTC conditioning regimen and Modified Bu/Cy conditioning regimen
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking University People's Hospital
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
This phase 2 study aims to confirm the efficacy observed in the prior phase 1 trial in Cohort 1 and to evaluate the safety of IFN-γ in combination with DLI in Cohort 2, the haploidentical donor alloSCT recipient cohort.
- Trial name
- NCT06529731
- Testing
- Interferon gamma-1b, Donor Leukocyte Infusion (DLI)
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- Sawa Ito, MD
Hematological Malignancies, Graft-versus-Host Disease (GVHD)
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide in addition to two-drug graft-versus-host disease (GVHD) prophylaxis…
- Trial name
- PTCYGVHD (NCT06799195)
- Testing
- Attenuated-dose Cyclophosphamide, High-dose Cyclophosphamide, Sirolimus
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- University of Nebraska
Obesity, Malignant Neoplasm
A Study to See if an iPhone Weight Management App Can Help Promote Weight Loss in Adolescents and Young Adults After a Stem Cell Transplant
This early phase I trial studies how well a behavioral weight loss intervention consisting of a smartphone application and coaching works for the promotion of weight loss in adolescents and young adults after a stem cell…
- Trial name
- NCT04453072
- Testing
- Interview, Media Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Jonsson Comprehensive Cancer Center
Acute Leukemia, Myelodysplastic Syndrome
Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
Study of QUAIL-100 in Patients With High Risk Acute Leukemia and Myelodysplastic Syndrome Who Have Received Hematopoietic Stem Cell Transplant
- Trial name
- NCT07573111
- Testing
- QUAIL-100
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Laguna Biotherapeutics, Inc.
Cutaneous T Cell Lymphoma (CTCL), Brentuximab Vedotin
Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance
Allogeneic hematopoietic stem cell transplantation (alloHSCT) showed efficacy in advanced-stage, high-risk, treatment sensitive cutaneous T-cell lymphomas (CTCL) in a prospective, propensity score-matched controlled study…
- Trial name
- BeCALM (NCT07178457)
- Testing
- Brentuximab Vedotin (Bv)
- Volunteers
- 84 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cancer and / or Hematological Malignancy, Hematopoetic Stem Cell Transplantation
Virtual Reality Intervention for Symptom Management in Stem Cell Transplantation
The goal of this clinical trial is to evaluate whether a virtual reality (VR) intervention based on the Symptom Management Model can reduce physical and psychosocial symptoms during hematopoietic stem cell transplantation (HSCT)…
- Conditions
- Cancer and / or Hematological Malignancy, Hematopoetic Stem Cell Transplantation, Nursing Interventions, Symptom Management
- Trial name
- NCT07145359
- Testing
- Virtual Reality Intervention
- Volunteers
- 30 people
- Sponsor
- Halic University
AML (Acute Myelogenous Leukemia)
Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT
This is a single-center, prospective, single-arm, exploratory clinical study. To explore the efficacy and safety of avapritinib in patients with recurrent acute myeloid leukemia after allogeneic hematopoietic stem cell…
- Trial name
- NCT06783790
- Testing
- Avapritinib, azacitidine, Venetoclax
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Critical Illness, Ventilated Patients
Critical Illness After Hematopoietic Cell Transplantation
This is a prospective, multicenter observational trial for patients who develop critical illness after hematopoietic cell transplantation.
- Conditions
- Critical Illness, Ventilated Patients, Hematopoetic Stem Cell Transplantation, Transplant Complication
- Trial name
- CARE-HCT (NCT07328724)
- Where
- 6 sites in China
- Volunteers
- 4,000 people
- Sponsor
- Peking University People's Hospital